Natural Alternative Sweeteners and Diabetes Management
Purpose of Review
The goal of this review is to discuss the data on natural alternative sweeteners and their effects on glucose homeostasis and other metabolic parameters within the past five years. We sought to answer whether common natural alternative sweeteners have a positive or negative effect on glucose control in both human and animal models, and whether the data supports their widespread use as a tool to help reduce the prevalence of diabetes and associated comorbid conditions.
Recent studies suggest that natural alternative sweeteners may reduce hyperglycemia, improve lipid metabolism, and have antioxidant effects particularly in those that have baseline diabetes.
Diabetes and metabolic syndrome have become a global healthcare crisis and the sugar overconsumption plays a major role. The use of artificial sweeteners has become more prevalent to improve insulin resistance in those with diabetes, obesity, and metabolic syndrome, although the evidence does not support this result. There are however some promising data to suggest that natural alternative sweeteners may be a better alternative to sugar and artificial sweeteners.
KeywordsNatural alternative sweeteners Diabetes Stevia Sugar alcohols Rare sugars
Compliance with Ethical Standards
Conflict of Interest
Emily Mejia and Dr. Michelle Pearlman declare that they have no conflict of interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Prata C, Zambonin L, Rizzo B, Maraldi T, Angeloni C, Vieceli Dalla Sega F, et al. Glycosides from Stevia rebaudiana bertoni possess insulin-mimetic and antioxidant activities in rat cardiac fibroblasts. Oxid Med Cell Longev. 2017;2017:3724545. https://doi.org/10.1155/2017/3724545.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Adult obesity facts. Center for Disease Control and Prevention. 2018. https://www.cdc.gov/obesity/data/adult.html. Accessed 6/23/19.
- 6.Organization WH. Global report on diabetes. 2016. 2017.Google Scholar
- 16.Aranda-González I, Moguel-Ordóñez Y, Chel-Guerrero L, Segura-Campos M, Betancur-Ancona D. Evaluation of the antihyperglycemic effect of minor steviol glycosides in normoglycemic and induced-diabetic Wistar rats. J Med Food. 2016;19(9):844–52. https://doi.org/10.1089/jmf.2016.0014.CrossRefPubMedGoogle Scholar
- 17.• Akbarzadeh S, Eskandari F, Tangestani H, Bagherinejad ST, Bargahi A, Bazzi P et al. The effect of Stevia rebaudiana on serum omentin and visfatin level in STZ-induced diabetic rats. Journal of dietary supplements. 2015;12(1):11-22. Proposed molecular mechanism for stevia’s insulin-mimetic properties. Google Scholar
- 19.Noronha JC, Braunstein CR, Glenn AJ, Khan TA, Viguiliouk E, Noseworthy R, et al. The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: a double-blind, randomized, controlled, acute feeding, equivalence trial. Diabetes Obes Metab. 2018;20(10):2361–70. https://doi.org/10.1111/dom.13374.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Han Y, Kwon E-Y, Yu M, Lee S, Kim H-J, Kim S-B, et al. A preliminary study for evaluating the dose-dependent effect of d-allulose for fat mass reduction in adult humans: a randomized, double-blind. Placebo-Controlled Trial Nutrients. 2018;10(2):160. https://doi.org/10.3390/nu10020160.CrossRefGoogle Scholar
- 22.• Ensor M, Williams J, Smith R, Banfield A, Lodder RA. Effects of three low-doses of D-tagatose on glycemic control over six months in subjects with mild type 2 diabetes mellitus under control with diet and exercise. Journal of endocrinology, diabetes & obesity. 2014;2(4):1057. Identifies minimum dosage required to see positive effects on blood glucose after six months of treatment. Google Scholar
- 23.•• Ensor M, Banfield AB, Smith RR, Williams J, Lodder RA. Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of endocrinology, diabetes & obesity. 2015;3(1). Results were reproducible with a longer treatment period with a larger and more diverse participant population. Google Scholar
- 25.• Shintani T, Yamada T, Hayashi N, Iida T, Nagata Y, Ozaki N et al. Rare sugar syrup containing D-allulose but not high-fructose corn syrup maintains glucose tolerance and insulin sensitivity partly via hepatic glucokinase translocation in Wistar rats. Journal of agricultural and food chemistry. 2017;65(13):2888-94. Evaluates the mechanism of action of rare sugars and suggests that RSS affects glucose metabolism through GK and increased glycogen levels. CrossRefGoogle Scholar
- 26.Iwasaki Y, Sendo M, Dezaki K, Hira T, Sato T, Nakata M, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. 2018;9(1). https://doi.org/10.1038/s41467-017-02488-y.
- 28.• Nagata Y, Kanasaki A, Tamaru S, Tanaka K. D-psicose, an epimer of D-fructose, favorably alters lipid metabolism in Sprague–Dawley rats. Journal of agricultural and food chemistry. 2015;63(12):3168–76. First study to show that allulose may modulate lipid absorption in the small intestine, explaining its hypolipidemic actions. CrossRefGoogle Scholar
- 29.• Hossain A, Yamaguchi F, Hirose K, Matsunaga T, Sui L, Hirata Y et al. Rare sugar D-psicose prevents progression and development of diabetes in T2DM model Otsuka Long-Evans Tokushima Fatty rats. Drug Design, Development and Therapy. 2015:525. doi: https://doi.org/10.2147/dddt.s71289. Long term (greater than 1 year) provides evidence supporting rare sugars’ role in decreasing inflammation.
- 31.Gray A. Nutritional recommendations for individuals with diabetes. Endotext [Internet]. MDText. com, Inc.; 2015.Google Scholar
- 32.Jain T, Grover K. Sweeteners in human nutrition. International Journal of Health Sciences and Research. 2015;5(5):439–51.Google Scholar
- 33.Wölnerhanssen BK, Cajacob L, Keller N, Doody A, Rehfeld JF, Drewe J, et al. Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects. American Journal of Physiology-Endocrinology and Metabolism. 2016;310(11):E1053–E61. https://doi.org/10.1152/ajpendo.00037.2016.CrossRefPubMedGoogle Scholar
- 34.Overduin J, Collet T-H, Medic N, Henning E, Keogh JM, Forsyth F, et al. Failure of sucrose replacement with the non-nutritive sweetener erythritol to alter GLP-1 or PYY release or test meal size in lean or obese people. Appetite. 2016;107:596–603. https://doi.org/10.1016/j.appet.2016.09.009.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Mohsenpour MA, Kaseb F, Nazemian R, Mozaffari-Khosravi H, Fallahzadeh H, Salehi-Abargouei A. The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: a phase I double-blind, three-way randomized cross-over clinical trial. Endocrinologia, diabetes y nutricion. 2019.Google Scholar
- 40.Gangoso A, Robben DM, Wesley MC, Rodriguez PRR, editors. Comparison of the glycemic response of white sugar and monk fruit sweetener among normoglycemic subjects. 7th International Scholars Conference Proceeding; 2018.Google Scholar
- 41.Liu H, Qi X, Yu K, Lu A, Lin K, Zhu J, et al. AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice. Food Funct. 2019. https://doi.org/10.1039/c8fo01486h.CrossRefGoogle Scholar